Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Payables (2020 - 2025)

Historic Payables for Neuphoria Therapeutics (NEUP) over the last 6 years, with Q4 2025 value amounting to $520709.0.

  • Neuphoria Therapeutics' Payables fell 6598.16% to $520709.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $520709.0, marking a year-over-year decrease of 6598.16%. This contributed to the annual value of $1.2 million for FY2025, which is N/A changed from last year.
  • Neuphoria Therapeutics' Payables amounted to $520709.0 in Q4 2025, which was down 6598.16% from $1.4 million recorded in Q3 2025.
  • Over the past 5 years, Neuphoria Therapeutics' Payables peaked at $2.3 million during Q2 2023, and registered a low of $520709.0 during Q4 2025.
  • Moreover, its 5-year median value for Payables was $1.4 million (2025), whereas its average is $1.4 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 1723.0% in 2023, then plummeted by 6598.16% in 2025.
  • Neuphoria Therapeutics' Payables (Quarter) stood at $2.0 million in 2021, then fell by 0.49% to $2.0 million in 2022, then grew by 17.23% to $2.3 million in 2023, then tumbled by 34.58% to $1.5 million in 2024, then plummeted by 65.98% to $520709.0 in 2025.
  • Its Payables was $520709.0 in Q4 2025, compared to $1.4 million in Q3 2025 and $1.2 million in Q2 2025.